Biologics

KeyBanc Capital Market's bull case for Catalent Inc (NYSE: CTLT) has come to an end. The company has taken the necessary steps to gain exposure to the high-growth biologics and gene therapy space, according to the sell-side firm.  The Analyst Donald Hooker downgraded Catalent from...

The FDA issued final guidelines Friday concerning the interchangeability of biosimilars with biologics with an intention to make the former easily available to patients, just as how generics are used for branded drugs. What Happened The FDA's latest guidelines outlined the studies a...

Stocks traded mostly lower today as investors digested a new set of earnings that were disappointing. A mixed housing data and a consumer sentiment coming in lower than expected was enough to tame the bulls as major indices finished the day mixed. Markets will be closed on Monday for Martin...

Here's a look at the top tickers trending on StockTwits.com. Ariad Pharmaceuticals On Friday morning, Ariad Pharmaceuticals (NASDAQ: ARIA) announced the commercial availability of Iclusig for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute...